Auswahl der wichtigsten Publikationen

  1. Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. Combined modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002;20:3061-3071.

  2. Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;21:3098-3104.

  3. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess C, Karstens JH, Liersch T, Schmidberger H, Raab R, for the German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer. N Engl J Med 2004;351:1731-40.

  4. Rödel F, Hoffmann J, Distel L, Herrmann M, Noistering T, Papadopoulos T, Sauer R, Rödel C. Survivin as a radio-resistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-87.

  5. Rödel C, Martus P, Papadopoulos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23: 8688-96.

  6. Weiss C, Wolze C, Engehausen DG, Ott O, Ott JO, Krause FS, Schrott KM, Dunst J, Sauer R, Rödel C. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy. J Clin Oncol 2006;24:2318-24.

  7. Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24:5536-44.

  8. Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R.  Multicenter phase II trial of chemoradiotherapy with oxaliplatin for rectal cancer. J Clin Oncol 2007;25:110-7.

  9. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H,  Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow up of 11 years. J Clin Oncol 2012;30:1926-33.

  10. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab R, Sülberg H, Wittekind C,  Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer G, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomized phase 3 trial. Lancet Oncol 2012;13:679-87.

  11. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S, Raab HR, Sauer R, Wittekind C, Rödel C. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: Updated results of the CAO/ARO/AIO-94 trial after a median follow-up of 11 years. J Clin Oncol 2014,32:1554-62.

  12. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16:979-89.

  13. Fokas E, Ströbel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, Hartmann A, Kaufmann M, Sauer R, Graeven U, Hoffmanns H, Raab HR, Hothorn T, Wittekind C, Rödel C. Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. J Natl Cancer Inst 2017, epub ahead of print.

Originalarbeiten (chronologisch)

  1. Rödel C, Fietkau R, Grabenbauer GG, Keilholz L, Martus P, Kessler R, Sauer R. Akuttoxizität der simultanen Radiochemotherapie des Rektumkarzinoms. Strahlenther Onkol 1997;173:414-20.

  2. Wendt TH, Grabenbauer GG, Rödel C, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A. Simultaneous radio-chemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.

  3. Grüner A, Grabenbauer GG, Rödel C, Weidenbecher M, Martus P, Iro H, Sauer R. Nasopharynxkarzinom: Nur Bestrahlung oder simultane Radiochemotherapie? Strahlenther Onkol 1999;175:591-96.

  4. Rödel C, Grabenbauer GG, Matzel KL, Schick C, Fietkau R, Papadopoulos T, Martus P, Hohenberger W, Sauer R. Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum 2000;43:312-19.

  5. Rödel C, Grabenbauer GG, Rödel F, Birkenhake S, Kühn R, Martus P, Fürsich D, Papadoupolos T, Dunst J, Sauer R. Apoptosis, p53, Ki-67 and bcl-2: possible predictors for successful bladder preservation by transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2000;46:1213-21.

  6. Grabenbauer GG, Schuchardt U, Buchfelder M, Rödel C, Gusek G, Marx M, Doerr HG, Fahlbusch R, Huk WJ, Wenzel D, Sauer R. Radiation therapy of optico-hypothalamic gliomas (OHG) – radiographic response, vision and late toxicity. Radiother Oncol 2000,54:239-45.

  7. Rödel C, Grabenbauer GG, Schick C, Papadopoulos T, Hohenberger W, Sauer R. Preoperative radiation with concurrent 5-fluorouracil for locally advanced primary T4-rectal cancer. Strahlenther Onkol 2000,176:161-67.

  8. Grabenbauer GG, Mühlfriedel C, Rödel F, Niedobitek G, Hornung J, Rödel C, Martus P, Iro H, Kirchner T, Steininger H, Sauer R, Weidenbecher M, Distel L. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1041-50.

  9. Grabenbauer GG, Rödel C, Paulus W, Gansland O, Schuchard U, Buchfelder M, Schrell U, Huk W, Sauer R. Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy. Strahlenther Onkol 2000;176:259-264.

  10. Rödel C, Dunst J, Grabenbauer GG, Kühn R, Papadopoulos T, Schrott KM, Sauer R: Radiotherapy is an effective treatment for high-risk T1-bladder cancer. Strahlenther Onkol 2001;177:82-88.

  11. Sauer R, Fietkau R, Wittekind C, Martus P, Rödel C, Hohenberger W, Jatzko G, Sabitzer H, Karstens JH, Becker H, Hess C, Raab R. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer: a progress report of a phase-III randomized trial. Strahlenther Onkol 2001,177: 173-81.

  12. Grabenbauer GG, Rödel C, Brunner T, Schulze-Mosgau S, Strnad V, Müller RG, Iro H, Sauer R. Interstitial brachytherapy with Ir-192 low-dos rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Strahlenther Onkol 2001:177:338-44.

  13. Rödel C, Grabenbauer GG, Kühn R, Dunst J, Papadopoulos T, Schrott KM, Sauer R. Invasive bladder cancer: organ preservation by radiochemotherapy. Front Radiat Ther Oncol, 2002;36:118-130.

  14. Rödel C, Grabenbauer GG, Papadoupolos T, Bigalke M, Günther K, Schick C, Sauer R, Rödel F. Apoptosis as cellular predictor of histopathological response to neoadjuvant radiochemo- therapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2002;52: 294-303.

  15. Rödel C, Grabenbauer GG, Kühn R, Dunst J, Zörcher T, Papadopoulos T, Schrott KM, Sauer R. Organ preservation in bladder cancer: Initial results of an intensified protocol of transurethral resection, radiation therapy and concurrent cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys 2002;52:1303-09.

  16. Rödel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiß C, Günther C, Schick C, Sauer R, Rödel C. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol, 2002;78:426-35.

  17. Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. Combined modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002;20:3061-71.

  18. Grabenbauer GG, Rödel C, Brunner Th, Hornung J, Kittel K, Schulze-Mosgau S, Steinhart H, Iro H, Sauer R. Neck dissection following radiochemotherapy of advanced head and neck cancer – for selected cases only? Radiother Oncol, 2003;66:57-63.

  19. Fuchs S, Rödel C, Brunner T, Iro H, Niedeobitek G, Sauer R, Grabenbauer GG. Patterns of failure following radiation with or without chemotherapy in patients with nasopharyngeal carcinoma. Onkologie 2003;26:12-18.

  20. Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F. Spontaneous and radiation induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003;55:1341-47.

  21. Grabenbauer GG, Suckorade O, Niedobitek G, Rödel F, Iro H, Rödel C, Schulze-Mosgau S, Distel L. Imbalance between proliferation and apoptosis may be responsible for treatment failure after postoperative radiotherapy in squamous cell carcinoma of the oropharynx. Oral Oncology 2003;39:459-69.

  22. Humeny A, Rödel F, Rödel C, Sauer R, Füzesi L, Becker CM, Efferth T. MDR 1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anticancer Res 2003;23(3B):2735-40.

  23. Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;21:3098-104.

  24. Günther K, Dimmler A, Rödel F, Reulbach U, Merkel S, Bittorf B, Matzel K, Papadopoulos T, Hohenberger W, Sauer R, Rödel C. P27 expression does not predict histopathological response to radiochemotherapy in rectal cancer. J Surg Res 2003;113:179-88.

  25. Göhl J, Merkel S, Rödel C, Hohenberger W: Can neoadjuvant radiochemo-therapy improve the results of multivisceral resections in advanced rectal carcinoma (cT4a). Int J Colorectal Dis 2003;5:436-41.

  26. Sauer R, Fietkau R, Wittekind C, Rödel C, Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH, Becker H, Hess C, Raab R. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trail CAO/ARO/AIO-94. Int J Colorectal Dis 2003;5:406-15.

  27. Ott OJ, Rödel C, Gramatzki M, Niedobitek G, Sauer R, Grabenbauer GG. Radiotherapy for stage I-III nodal low-grade Non-Hodgkin’s Lymhoma. Strahlenther Onkol 2003;179:694-701.

  28. Rödel F, Hantschel M, Hildebrandt G, Schultze-Mosgau S, Rödel C, Herrmann M, Sauer R, Voll RE. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-kB) in EA.hy.926 endothelial cells after low-dose X-irradiation. Int J Radiat Biol 2004;80:115-23.

  29. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess C, Karstens JH, Liersch T, Schmidberger H, Raab R, for the German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer. N Engl J Med 2004;351:1731-40.

  30. Rödel F, Hoffmann J, Distel L, Herrmann M, Noistering T, Papadopoulos T, Sauer R, Rödel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-87.

  31. Weiss C, Rödel F, Wolf I, Papadoupoulos T, Schrott KM, Sauer R, Rödel C. Combined modality treatment and organ preservation in bladder cancer: Do molecular marker predict outcome? Strahlenther Onkol 2005;181:213-22.

  32. Akcetin Z, Todorov J, Tuzel E, Engehausen DG, Krause FS, Sauer R, Schrott KM, Rödel C. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer. Anticancer Res 2005;25:1623-28.<